Literature DB >> 19401561

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

Aldo M Roccaro1, Antonio Sacco, Brian Thompson, Xavier Leleu, Abdel Kareem Azab, Feda Azab, Judith Runnels, Xiaoying Jia, Hai T Ngo, Molly R Melhem, Charles P Lin, Domenico Ribatti, Barrett J Rollins, Thomas E Witzig, Kenneth C Anderson, Irene M Ghobrial.   

Abstract

Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma (MM) pathogenesis and disease progression. Nevertheless, little is known about the characteristics of MM at the epigenetic level and specifically how microRNAs regulate MM progression in the context of the bone marrow milieu. Therefore, we performed microRNA expression profiling of bone marrow derived CD138(+) MM cells versus their normal cellular counterparts and validated data by qRT-PCR. We identified a MM-specific microRNA signature characterized by down-expression of microRNA-15a/-16 and overexpression of microRNA-222/-221/-382/-181a/-181b (P < .01). We investigated the functional role of microRNA-15a and -16 and showed that they regulate proliferation and growth of MM cells in vitro and in vivo by inhibiting AKT serine/threonine-protein-kinase (AKT3), ribosomal-protein-S6, MAP-kinases, and NF-kappaB-activator MAP3KIP3. Moreover, miRNA-15a and -16 exerted their anti-MM activity even in the context of the bone marrow milieu in vitro and in vivo. These data indicate that microRNAs play a pivotal role in the biology of MM and represent important targets for novel therapies in MM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401561      PMCID: PMC2710922          DOI: 10.1182/blood-2009-01-198408

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).

Authors:  Dharminder Chauhan; Paola Neri; Mugdha Velankar; Klaus Podar; Teru Hideshima; Mariateresa Fulciniti; Pierfrancesco Tassone; Noopur Raje; Constantine Mitsiades; Nicholas Mitsiades; Paul Richardson; Leigh Zawel; Mary Tran; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

3.  The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Xiaoying Jia; Judith Runnels; Hai T Ngo; Anne-Sophie Moreau; Mena Farag; Joel A Spencer; Costas M Pitsillides; Evdoxia Hatjiharissi; Aldo Roccaro; Garrett O'Sullivan; Douglas W McMillin; Daisy Moreno; Tanyel Kiziltepe; Ruben Carrasco; Steven P Treon; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

4.  MicroRNA expression in cytogenetically normal acute myeloid leukemia.

Authors:  Guido Marcucci; Michael D Radmacher; Kati Maharry; Krzysztof Mrózek; Amy S Ruppert; Peter Paschka; Tamara Vukosavljevic; Susan P Whitman; Claudia D Baldus; Christian Langer; Chang-Gong Liu; Andrew J Carroll; Bayard L Powell; Ramiro Garzon; Carlo M Croce; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

5.  Targeting NF-kappaB in Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Jérôme Eeckhoute; Xiaoying Jia; Aldo M Roccaro; Anne-Sophie Moreau; Mena Farag; Antonio Sacco; Hai T Ngo; Judith Runnels; Molly R Melhem; Nicolas Burwick; Abdelkareem Azab; Feda Azab; Zachary Hunter; Evdoxia Hatjiharissi; Daniel R Carrasco; Steven P Treon; Thomas E Witzig; Teru Hideshima; Myles Brown; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

6.  Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma.

Authors:  Robert W Chen; Lynne T Bemis; Carol M Amato; Han Myint; Hung Tran; Diane K Birks; S Gail Eckhardt; William A Robinson
Journal:  Blood       Date:  2008-05-15       Impact factor: 22.113

7.  The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities.

Authors:  Désirée Bonci; Valeria Coppola; Maria Musumeci; Antonio Addario; Raffaella Giuffrida; Lorenzo Memeo; Leonardo D'Urso; Alfredo Pagliuca; Mauro Biffoni; Catherine Labbaye; Monica Bartucci; Giovanni Muto; Cesare Peschle; Ruggero De Maria
Journal:  Nat Med       Date:  2008-10-19       Impact factor: 53.440

8.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

9.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.

Authors:  Flavia Pichiorri; Sung-Suk Suh; Marco Ladetto; Michael Kuehl; Tiziana Palumbo; Daniela Drandi; Cristian Taccioli; Nicola Zanesi; Hansjuerg Alder; John P Hagan; Reinhold Munker; Stefano Volinia; Mario Boccadoro; Ramiro Garzon; Antonio Palumbo; Rami I Aqeilan; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-26       Impact factor: 11.205

10.  A novel function for HSF1-induced mitotic exit failure and genomic instability through direct interaction between HSF1 and Cdc20.

Authors:  Y J Lee; H J Lee; J S Lee; D Jeoung; C M Kang; S Bae; S J Lee; S H Kwon; D Kang; Y S Lee
Journal:  Oncogene       Date:  2007-12-03       Impact factor: 9.867

View more
  131 in total

1.  Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells.

Authors:  Mu Hao; Li Zhang; Gang An; Weiwei Sui; Zhen Yu; Dehui Zou; Yan Xu; Hong Chang; Lugui Qiu
Journal:  J Hematol Oncol       Date:  2011-09-22       Impact factor: 17.388

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

3.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

4.  Dysregulation of miRNAs in AL amyloidosis.

Authors:  Liangping Weng; Brian H Spencer; Pamela T SoohHoo; Lawreen H Connors; Carl J O'Hara; David C Seldin
Journal:  Amyloid       Date:  2011-08-11       Impact factor: 7.141

5.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

6.  Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression.

Authors:  Lei Zhang; Lin Zhou; Meng Shi; Yong Kuang; Lei Fang
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

7.  Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance.

Authors:  Weixin Wang; Youn K Shim; Joel E Michalek; Emily Barber; Layla M Saleh; Byeong Yeob Choi; Chen-Pin Wang; Norma Ketchum; Rene Costello; Gerald E Marti; Robert F Vogt; Ola Landgren; Katherine R Calvo
Journal:  J Toxicol Environ Health A       Date:  2020-04-14

Review 8.  MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.

Authors:  Luna Soley; Carolyne Falank; Michaela R Reagan
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

9.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

10.  Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Emanuel N Husu; Costas Pitsillides; Steven Vesole; Abdel Kareem Azab; Feda Azab; Molly Melhem; Hai T Ngo; Phong Quang; Patricia Maiso; Judith Runnels; Mei-Chih Liang; Kwok-Kin Wong; Charles Lin; Irene M Ghobrial
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.